Recon: FDA approves new Bristol Myers cancer immunotherapy; VRBPAC to discuss boosters, strain selection at 6 April meeting
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy